Satisfaction and compliance in hormonal contraception: The result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy

被引：7

作者：

Crosignani P.G. ^{[1
]}

Nappi C. ^{[2
,19
]}

Ronsini S. ^{[3
,23
]}

Bruni V. ^{[4
,10
]}

Marelli S. ^{[4
]}

Sonnino D. ^{[5
]}

Affronti G. ^{[6
]}

Benagiano G. ^{[7
]}

Benedetto C. ^{[8
]}

Bolis G. ^{[9
]}

Cianci A. ^{[11
]}

Fedele L. ^{[12
]}

Garsia A. ^{[13
]}

Genazzani A.R. ^{[14
]}

Gherzi R. ^{[15
]}

Masellis G. ^{[16
]}

Melis G. ^{[17
]}

Moscarini M. ^{[18
]}

Piccione E. ^{[20
]}

Quartararo P. ^{[21
]}

Ragni N. ^{[22
]}

Scagliola P. ^{[24
]}

Schönauer S. ^{[25
]}

Sismondi P. ^{[26
]}

Venturini P.L. ^{[27
]}

Volpe A. ^{[28
]}

Zullo F. ^{[29
]}

机构：

[1] II Institute of Obstetrics and Gynaecology, University of Milan, Milan

[2] Department of Obstetric-Gynaecological, Urological Sciences and Reproduction Medicine, University of Naples, Naples

[3] Department of Maternal and Children's Sciences, ASL SA 3 San Luca Hospital, Vallo della Lucania, SA

[4] Department of Gynaecology, Perinatology and Human Reproduction, University of Florence, Florence

[5] Medical Affairs Department, Janssen-Cilag SpA, Cologno Monzese, MI

[6] Azienda Ospedaliera di Perugia, Perugia

[7] Università degli Studi di Roma La Sapienza, Roma

[8] Azienda Ospedaliera O.I.R.M.S. Anna, Torino

[9] Azienda Ospedaliera S. Paolo, Milano

[10] Policnico Careggi, Università degli Studi di Firenze, Firenze

[11] Azienda Ospedaliera Universitaria V. Emanuele-Ferrarotto-S. Bambino, Catania

[12] Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano

[13] Azienda Ospedaliera Niguarda Cà Granda, Milano

[14] Università degli Studi di Pisa, Pisa

[15] Azienda Ospedaliera Maggiore della Carità, Novara

[16] Ospedale Civile Ramazzini, Carpi, MO

[17] Ospedale S. Giovanni di Dio, Cagliari

[18] Azienda Ospedaliera S. Andrea, Roma

[19] Università degli Studi Federico II, Napoli

[20] Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma

[21] Policlinico Paolo Giaccone, Palermo

[22] Università degli Studi di Genova, Genova

[23] Ospedale San Luca, Vallo della Lucania, SA

[24] Spedali Civili di Brescia, Brescia

[25] Azienda Ospedaliera Ospedale Policlinico Consorziale, Bari

[26] Azienda Sanitaria Ospedaliera Ordine Mauriziano, Torino

[27] Istituto Giannini Gaslini, Genova

[28] Azienda Ospedaliera di Modena, Modena

[29] Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro

来源：

BMC Women's Health | / 9卷 / 1期

关键词：

Oral Contraceptive; Contraceptive Method; Unintended Pregnancy; Ethinylestradiol; Bioelectrical Impedance Analysis;

D O I：

10.1186/1472-6874-9-18

中图分类号：

学科分类号：

摘要：

Background: For many women finding the right contraceptive method can be challenging and consistent and correct use over a lifetime is difficult. Even remembering to take a birth control pill every day can be a challenge. The primary objective of this study was to evaluate women's experience with a weekly ethinylestradiol/norelgestromin contraceptive patch (EE/NGMN patch), given new technologies recently developed in hormonal contraception to increase women's options in avoiding daily dosing. Methods: In 24 Italian sites, 207 women received the EE/NGMN patch for up to 6 cycles. At study end, overall satisfaction and preference, as well as compliance, efficacy and safety, were evaluated. Results: 175 women (84.5%) completed the study. The overall satisfaction rate was 88%; convenience and once-a-week frequency of the patch were especially appreciated. At baseline, 82 women (39.4%) were using a contraceptive method, mainly oral contraceptives and barrier methods, but only 45.1% were very satisfied/satisfied; after 6 months with the patch, 86.3% of this subset was very satisfied/satisfied. Considering the method used in the 3 months before the study entry, 78.1% strongly preferred/preferred the patch, for convenience (53.9%), ease of use/ simplicity (28.9%), fewer (9.2%) and less severe (2.6%) side effects. Compliance was very high: 1034/1110 cycles (93.2%) were completed with perfect compliance and the mean subject's compliance score was 90%. One on-therapy pregnancy occurred. The patch was safe and well tolerated: adverse events frequency was low, with predominantly single reports of each event. Most of them started and subsided during cycle 1. Conclusion: This study demonstrated that the EE/NGMN patch is associated with high satisfaction levels and excellent compliance. At study end, the majority of women indicated that they would continue using the patch. © 2009 Crosignani et al; licensee BioMed Central Ltd.

引用

共 37 条

[21]

Archer D.F., Cullins V., Creasy G.W., Fisher A.C., The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy, Contraception, 69, 3, pp. 189-195, (2004)

[22]

Harel Z., Riggs S., Vaz R., Flanagan P., Dunn K., Harel D., Adolescents' experience with the combined estrogen and progestin transdemal contraceptive method Ortho Evra, J Pediatr Adolesc Gynecol, 18, pp. 85-90, (2005)

[23]

Zacur H.A., Hedon B., Mansour D., Shangold G.A., Fisher A.C., Creasy G.W., Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions, Fertil Steril, 77, 2 SUPPL. 2, (2002)

[24]

Sibai B.M., Odlind V., Meador M.L., Shangold G.A., Fisher A.C., Creasy G.W., A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra), Fertil Steril, 77, 2 SUPPL. 2, (2002)

[25]

Jick S.S., Kaye J.A., Li L., Jick H., Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol, Contraception, 76, 1, pp. 4-7, (2007)

[26]

Martinez F., Avecilla A., Combined hormonal contraception and venous thromboembolism, Eur J Contracept Reprod Health Care, 12, 2, pp. 97-106, (2007)

[27]

Cole J.A., Norman H., Doherty M., Walker A.M., Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users, Obstet Gynecol, 109, 2 PART 1, pp. 339-346, (2007)

[28]

Jick S.S., Kaye J.A., Russmann S., Jick H., Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol, Contraception, 73, pp. 223-228, (2006)

[29]

ClinicalTrials.gov

[30]

Jakimiuk A., Madalenet P., Chernev T., Cha'Ban K., Bergmans P., Preik M., Lee E., Transdermal contraception is associated with high levels of patient satisfaction and compliance [abstract], Eur J Contracept Reprod Health Care, 11, SUPPL. 1, pp. 68-69, (2006)

← 1 2 3 4 →